Reading DYN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DYN free→Reading DYN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DYN free→QuarterlyIQ Insights · DYN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 3, 2026, the Company issued a press release announcing full enrollment of the REC of its Phase 1/2 ACHIEVE trial of z-basivarsen in individuals with DM1 with 71 participants. Additionally, the Company announced the following key milestones for z-basivarsen: • Topline data from the ACHIEVE REC are planned for the first quarter of 2027 to support a potential Biologics License Application (“BLA”) for U.S. Accelerated Approval in the third quarter of 2027. • The Company inte…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.